Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.

Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, WHO; Shankar-Hari, Manu; L Vale, Claire; J Godolphin, Peter; Fisher, David; P T Higgins, Julian; Spiga, Francesca; Savovic, Jelena; Tierney, Jayne; Baron, Gabriel; S Benbenishty, Julie; R Berry, Lindsay; Broman, Niklas; Biasi Cavalcanti, Alexandre; Colman, Roos; L De Buyser, Stefanie; P G Derde, Lennie; Domingo, Pere; Faridah Omar, Sharifah; Fernandez-Cruz, Ana; Feuth, Thijs; Garcia, Felipe; Garcia-Vicuna, Rosario; Gonzalez-Alvaro, Isidoro; C Gordon, Anthony; Haynes, Richard; Hermine, Olivier; W Horby, Peter; K Horick, Nora; Kumar, Kuldeep; N Lambrecht, Bart; J Landray, Martin; Leal, Lorna; J Lederer, David; Lorenzi, Elizabeth; Mariette, Xavier; Merchante, Nicolas; Arisah Misnan, Nor; V Mohan, Shalini; C Nivens, Michael; Oksi, Jarmo; A Perez-Molina, Jose; Pizov, Reuven; Porcher, Raphael; Postma, Simone; Rajasuriar, Reena; V Ramanan, Athimalaipet; Ravaud, Philippe; D Reid, Pankti; Rutgers, Abraham

doi:10.1001/jama.2021.11330

Public

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.

Published in JAMA • Aug 10, 2021

NobleIDNI0P54W01R18S86

Authors:

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

,

Manu Shankar-Hari

,

Claire L Vale

Abstract

Importance: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. Objective: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-caus...

Discussions